Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Tolvaptan Reduces Long-Term Total Medical Expenses and Length of Stay in Aquaporin-Defined Responders.

Imamura T, Kinugawa K, Nitta D, Komuro I.

Int Heart J. 2016 Sep 28;57(5):593-9. doi: 10.1536/ihj.16-007. Epub 2016 Sep 13.

2.
3.

Predictors for Tolvaptan Treatment and Future Perspectives.

Nitta D.

Int Heart J. 2016 Jul 27;57(4):391-2. doi: 10.1536/ihj.16-256. Epub 2016 Jul 11. No abstract available.

4.

Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.

Kadota M, Ise T, Yagi S, Iwase T, Akaike M, Ueno R, Kawabata Y, Hara T, Ogasawara K, Bando M, Bando S, Matsuura T, Yamaguchi K, Yamada H, Soeki T, Wakatsuki T, Sata M.

Int Heart J. 2016 Jul 27;57(4):461-5. doi: 10.1536/ihj.15-491. Epub 2016 Jun 29.

5.

Mid-Term Administration of Tolvaptan Improves Renal Function Accompanied by Dose-Reduction in Furosemide in Aquaporin-Defined Responders.

Imamura T, Kinugawa K.

Int Heart J. 2015;56(6):686-7. doi: 10.1536/ihj.15-298. Epub 2015 Nov 9. No abstract available.

6.

Response to "clarification of enrolled subjects in tolvaptan HF trials".

Feldman AM, Hamad E, Tsai E, Zhu W, Tilley DG, Alvarez R, Cheung JY.

Clin Pharmacol Ther. 2014 Dec;96(6):661. doi: 10.1038/clpt.2014.191. Epub 2014 Sep 18. No abstract available.

PMID:
25232760
7.

Clarification of enrolled subjects in tolvaptan HF trials.

Blais J, Chiodo J 3rd, Friend K, Shoaf S.

Clin Pharmacol Ther. 2014 Dec;96(6):660. doi: 10.1038/clpt.2014.190. Epub 2014 Sep 18. No abstract available.

PMID:
25232759
8.

Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.

Lin TE, Adams KF Jr, Patterson JH.

Heart Fail Clin. 2014 Oct;10(4):607-20. doi: 10.1016/j.hfc.2014.07.009. Review.

PMID:
25217436
9.

Awareness of the vasopressin system in heart failure.

Sato N.

Circ J. 2014;78(9):2157-8. Epub 2014 Aug 4. No abstract available.

10.

Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure.

Imamura T, Kinugawa K, Fujino T, Inaba T, Maki H, Hatano M, Yao A, Komuro I.

Circ J. 2014;78(9):2240-9. Epub 2014 Jun 20.

11.

Therapeutic potential of vasopressin-receptor antagonists in heart failure.

Izumi Y, Miura K, Iwao H.

J Pharmacol Sci. 2014;124(1):1-6. Epub 2014 Jan 7. Review.

12.

Vasopressin receptor antagonists: from pivotal trials to current practice.

Kalra A, Maharaj V, Goldsmith SR.

Curr Heart Fail Rep. 2014 Mar;11(1):10-8. doi: 10.1007/s11897-013-0175-3. Review.

PMID:
24197791
13.

Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.

Hauptman PJ, Burnett J, Gheorghiade M, Grinfeld L, Konstam MA, Kostic D, Krasa HB, Maggioni A, Ouyang J, Swedberg K, Zannad F, Zimmer C, Udelson JE; Everest Investigators.

J Card Fail. 2013 Jun;19(6):390-7. doi: 10.1016/j.cardfail.2013.04.001. Epub 2013 May 14.

PMID:
23743487
14.

Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.

Hori M.

Future Cardiol. 2013 Mar;9(2):163-76. doi: 10.2217/fca.13.3.

PMID:
23463968
15.

Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial.

Butler J, Subacius H, Vaduganathan M, Fonarow GC, Ambrosy AP, Konstam MA, Maggioni A, Mentz RJ, Swedberg K, Zannad F, Gheorghiade M; EVEREST Investigators.

J Am Coll Cardiol. 2013 Feb 5;61(5):571-9. doi: 10.1016/j.jacc.2012.10.025. Epub 2012 Dec 12.

16.

Are all clinical trial sites created equal?

Bhatt DL, Cavender MA.

J Am Coll Cardiol. 2013 Feb 5;61(5):580-1. doi: 10.1016/j.jacc.2012.10.024. Epub 2012 Dec 12. No abstract available.

17.

Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Lanfear DE, Sabbah HN, Goldsmith SR, Greene SJ, Ambrosy AP, Fought AJ, Kwasny MJ, Swedberg K, Yancy CW, Konstam MA, Maggioni AP, Zannad F, Gheorghiade M; EVEREST trial investigators.

Circ Heart Fail. 2013 Jan;6(1):47-52. doi: 10.1161/CIRCHEARTFAILURE.112.970012. Epub 2012 Dec 12.

18.

Hyponatremia and outcomes in patients with heart failure.

Goldsmith SR.

Heart. 2012 Dec;98(24):1761-2. doi: 10.1136/heartjnl-2012-302854. No abstract available.

PMID:
23204533
19.

Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Vaduganathan M, Ambrosy AP, Greene SJ, Mentz RJ, Subacius HP, Maggioni AP, Swedberg K, Nodari S, Zannad F, Konstam MA, Butler J, Gheorghiade M; EVEREST trial investigators.

Circ Heart Fail. 2012 Nov;5(6):750-8. doi: 10.1161/CIRCHEARTFAILURE.112.970525. Epub 2012 Oct 9.

20.

[Tolvaptan (vasopressin receptor antagonist)].

Inomata T.

Nihon Rinsho. 2011 Nov;69 Suppl 9:408-11. Review. Japanese. No abstract available.

PMID:
22724238

Supplemental Content

Loading ...
Support Center